Alexa B Schrock

Alexa B Schrock

UNVERIFIED PROFILE

Are you Alexa B Schrock?   Register this Author

Register author
Alexa B Schrock

Alexa B Schrock

Publications by authors named "Alexa B Schrock"

Are you Alexa B Schrock?   Register this Author

81Publications

3390Reads

38Profile Views

Clinicopathologic Characteristics of BRG1-Deficient Non-Small Cell Lung Cancer.

J Thorac Oncol 2020 Jan 24. Epub 2020 Jan 24.

Center for Integrated Diagnostics, Department of Pathology, Massachusetts General Hospital. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.01.002DOI Listing
January 2020

Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.

Clin Colorectal Cancer 2019 Dec 4;18(4):307-309. Epub 2019 Sep 4.

Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2019.08.001DOI Listing
December 2019

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with -mutant non-small cell lung cancer and emergent amplification.

Lung Cancer (Auckl) 2019 12;10:21-26. Epub 2019 Mar 12.

Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/LCTT.S190403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419586PMC
March 2019

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib.

J Thorac Oncol 2019 02;14(2):e27-e29

Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.160DOI Listing
February 2019

Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.

J Thorac Oncol 2019 02;14(2):e29-e30

City of Hope Comprehensive Cancer Center, Duarte, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.10.169DOI Listing
February 2019

Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.

J Thorac Oncol 2019 01 26;14(1):54-62. Epub 2018 Sep 26.

Department of Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.09.014DOI Listing
January 2019

Dramatic response to alectinib in a lung cancer patient with a novel fusion and an acquired ALK T1151K mutation.

Lung Cancer (Auckl) 2018 8;9:111-116. Epub 2018 Nov 8.

Chao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/LCTT.S186804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234987PMC
November 2018

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

Lung Cancer 2018 10 31;124:86-89. Epub 2018 Jul 31.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183050
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.07.043DOI Listing
October 2018

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.

Cancer Discov 2018 07 17;8(7):822-835. Epub 2018 May 17.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030433PMC
July 2018

WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.

J Thorac Oncol 2018 07;13(7):e122-e123

Foundation Medical, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.03.003DOI Listing
July 2018

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

J Clin Oncol 2018 04 26;36(12):1199-1206. Epub 2018 Jan 26.

Jessica J. Lin, Satoshi Yoda, Beow Y. Yeap, Ibiayi Dagogo-Jack, Nicholas A. Jessop, Ginger Y. Jiang, Long P. Le, Aaron N. Hata, Justin F. Gainor, Anthony J. Iafrate, and Alice T. Shaw, Massachusetts General Hospital, Boston; Alexa B. Schrock, Kyle Gowen, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, and Vincent A. Miller, Foundation Medicine, Cambridge, MA; Viola W. Zhu and Sai-Hong Ignatius Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA; Melissa L. Johnson, Sarah Cannon Research Institute; and Christine M. Lovly, Vanderbilt-Ingram Cancer Center, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.2294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903999PMC
April 2018

EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?

J Thorac Oncol 2018 03;13(3):e33-e34

Foundation Medicine, Inc., Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.10.005DOI Listing
March 2018

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

Lung Cancer 2017 12 24;114:108-110. Epub 2017 Aug 24.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.08.018DOI Listing
December 2017

-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.

Lung Cancer (Auckl) 2017 6;8:241-247. Epub 2017 Dec 6.

Department of Medicine-Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA.

View Article

Download full-text PDF

Source
https://www.dovepress.com/cis-oriented-solvent-front-egfr-g7
Publisher Site
http://dx.doi.org/10.2147/LCTT.S147129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723122PMC
December 2017

Genomic Profiling of Small-Bowel Adenocarcinoma.

JAMA Oncol 2017 Nov;3(11):1546-1553

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.1051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710195PMC
November 2017

BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.

J Clin Oncol 2017 Aug 9;35(23):2624-2630. Epub 2017 May 9.

Jeremy C. Jones, Lindsay A. Renfro, Ben Y. Zhang, Pashtoon M. Kasi, Jesse S. Voss, Alexis D. Leal, Joleen M. Hubbard, Benjamin R. Kipp, Robert R. McWilliams, and Axel Grothey, Mayo Clinic, Rochester, MN; Humaid O. Al-Shamsi, Scott Kopetz, and Robert A. Wolff, The University of Texas MD Anderson Cancer Center, Houston, TX; and Alexa B. Schrock, Andrew Rankin, James Sun, Jeffrey Ross, and Siraj M. Ali, Foundation Medicine, Cambridge, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.4394
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.4394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549454PMC
August 2017

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

J Thorac Oncol 2017 07;12(7):e89-e90

Memorial Cancer Institute, Memorial Healthcare System, Hollywood, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.02.017DOI Listing
July 2017

Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.

Clin Lung Cancer 2017 05 11;18(3):e211-e213. Epub 2016 Nov 11.

Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.11.001DOI Listing
May 2017

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 05 11;12(5):872-877. Epub 2017 Jan 11.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403618PMC
May 2017

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

Lung Cancer 2017 04 9;106:110-114. Epub 2017 Feb 9.

Department of Medicine, Division of Hematology-Oncology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.02.005DOI Listing
April 2017

CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays.

J Thorac Oncol 2017 02;12(2):e19-e20

Clinical Development, Foundation Medicine, Inc., Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.11.2217DOI Listing
February 2017

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

J Thorac Oncol 2016 09 22;11(9):1493-502. Epub 2016 Jun 22.

Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.06.004DOI Listing
September 2016

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.

Lung Cancer 2016 07 22;97:48-50. Epub 2016 Apr 22.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, Orange, CA 92868, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.04.013DOI Listing
July 2016

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

J Thorac Oncol 2014 Dec;9(12):1821-5

*Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; †Foundation Medicine, Inc., Cambridge, Massachusetts; and ‡Departmente of Pathology and Laboratory Medicine, Albany Medical Center, Albany, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000368DOI Listing
December 2014